Low-molecular-weight heparin in the management of Trousseau's syndrome

Cancer

Volumn 80, Issue 4, 1997, Pages 649-655

  Walsh McMonagle, Denise ^a   Green, David ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anticoagulants; Cancer patients; Low molecular weight heparin; Thrombosis

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

CANCER; CASE REPORT; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOPHLEBITIS;

ADULT; ANTICOAGULANTS; ENOXAPARIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PARANEOPLASTIC SYNDROMES; THROMBOEMBOLISM; THROMBOSIS;

EID: 0030853997     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970815)80:4<649::AID-CNCR1>3.0.CO;2-I     Document Type: Review

References (77)

1. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris. London: New Sydenham Society, 1865:282-332.
2. Sack GH, Levin J, Bell W. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathologic, and therapeutic features. Medicine 1977;56:1-37.
3. Gore JM, Applebaum JS, Greene HL, Dexter L, Dalen JE. Occult cancer in patients with deep venous thrombosis. Arch Intern Med 1987;147:556-60.
4. Goldberg RJ, Seneff M, Gore JM. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med 1987;147:251-3.
5. Kakkar VV, Howe CT, Nicolaides AN, Renny JTG, Clarke MB. Deep vein thrombosis of legs: Is there a high risk population? Am J Surg 1970;120:527-30.
6. O'Connor NTJ, Cederholm-Williams SA, Fletcher EW, Allington M, Sharp AA. Significance of idiopathic deep venous thrombosis. Postgrad Med J 1984;60:275-7.
7. Aderka D, Brown A, Zelikovski A, Pinkhas J. Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer 1986;57:1846-9.
8. Griffin MR, Stanson AW, Brown ML, Hauser MF, O'Fallon M, Anderson HM, et al. Deep venous thrombosis and pulmonary embolism: risk of subsequent malignant neoplasia. Arch Intern Med 1987;147:907-11.
9. Donati MB. Cancer and thrombosis: from Phlegmasia Alba Dolens to transgenic mice. Thromb Haemostas 1995;74:278-81.
10. Bell WR, Starksen NF, Portefield JK. Trousseau's syndrome: devastating coagulopathy in the absence of heparin. Am J Med 1985;79:423-30.
11. Kazmier FJ, Bowie EJW, Hagedorn AB, Owen CA. Treatment of intravascular coagulation and fibrinolysis (ICF) syndrome. Mayo Clin Proc 1974;49:665-72.
12. Minna JD, Bunn PA Jr. Paraneoplastic syndromes. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 3rd edition. Philadelphia: JB Lippincott, 1989:1920-40.
13. Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in patients with cancer. J Med 1975;6:61-4.
14. Sproule EE. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938;34:566-85.
15. Pineo GF, Brain ML, Galkes AS, Hirsh J, Hatton MWC, Regoeczi E. Tumors, mucus production and hypercoaguability. Ann N Y Acad Sci 1974;230:262-70.
16. Schreiber DP, Kapp DS. Axillary-subclavian vein thrombosis following combination chemotherapy and radiation. Int J Radiat Oncol Biol Phys 1986; 12:391-5.
17. Wilson CB, Lambert HE, Scott RD. Subclavian and axillary vein thrombosis following radiotherapy for carcinoma of the breast. Clin Radiol 1987;38:95-6.
18. Weiss B, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep 1981;65:677-9.
19. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five drug chemotherapy regimen. Cancer 1984; 54:1264-8.
20. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-8.
21. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992;79:543-53.
22. Ludmerer KM, Kissane JM. Microangiopathic anemia and disseminated intravascular coagulation in an elderly woman. Am J Med 1983;74:1052-60.
23. Case records of the Massachusetts General Hospital. N Engl J Med 1968;278:955-61, 1968;279:1279-86, 1969;280-265-70, 1995;332:1700-7 .
24. Case records of the Massachusetts General Hospital. N Engl J Med 1968;278:955-61, 1968;279:1279-86, 1969;280-265-70, 1995;332:1700-7 .
25. Case records of the Massachusetts General Hospital. N Engl J Med 1968;278:955-61, 1968;279:1279-86, 1969;280-265-70, 1995;332:1700-7 .
26. Case records of the Massachusetts General Hospital. N Engl J Med 1968;278:955-61, 1968;279:1279-86, 1969;280-265-70, 1995;332:1700-7 .
27. Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost 1992;18:353-72.
28. Naschitz JE, Schechter L, Chang JB. Intermittent claudication associated with cancer: case studies. Angiology 1987;9:696-704.
29. Naschitz JE, Yeshurun D, Abramson J, Eldar S, Chouri H, Kedar S, et al. Ischemic heart disease precipitated by occult cancer. Cancer 1992;69:2712-20.
30. Naschitz JE, Yeshurun D, Abrahamson J. Arterial occlusive disease in occult cancer. Am Heart J 1992;124:738-45
31. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbult J, Wilhamson RCN. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995;346: 1004-5.
32. Lindahl AK, Abildgaard U, Stokke F. Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb Res 1990;59:651-6.
33. Moake JL. Hypercoagulable states. Adv Intern Med 1990; 35;235-48.
34. Edwards RL, Rickles FR, Cronlund M. Abnormalities of blood coagulation in patients with cancer: mononuclear cell tissue factor generation. J Lab Clin Med 1987;98:917-28.
35. Gordon SG, Cross BA. A factor X-activating cysteine protease from malignant tissue. J Clin Invest 1981;67:1665-71.
36. Gordon SG, Franks JL, Lewis B. Cancer procoagulant A: a factor X-activating procoagulant from malignant tissue. Thromb Res 1975;5:127-37.
37. Rogers JS, Murgo AJ, Fontana JA, Raich PC. Chemotherapy of breast cancer decreases plasma protein C and protein S. J Clin Oncol 1988;6:276-81.
38. Hajjar KA. Fibrinolysis revisited: new insights into the pathobiology of cancer. Vessels 1996;2:9-16.
39. O'Reilly M, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-92.
40. Bastida E, Ordinas A. Platelet contribution to the formation of metastatic foci: the role of cancer cell-induced platelet activation. Haemostasis 1988;18:29-36.
41. Gasic GJ, Catalfamo JL, Gasic TB, Advalovic N. In vitro mechanism of platelet aggregation by purified plasma membrane vesicles shed by mouse 15091 A tumor cells. In: Donati I, editor. Malignancy and the haemostatic system. New York: Raven Press, 1981:27-33.
42. Rickles FR, Edwards RL: Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14-31.
43. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320-7.
44. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209-15.
45. Warren B, Vales O. The adhesion of thromboplastic tumor emboli to vessel wall in vitro. Br J Exp Pathol 1972;153:301-13.
46. Thilo-Korner DGS, Freshney RJ. The endothelial cell: a pluripotent control cell of the vessel wall. Basel: Kerger, 1983.
47. Thulesium O. The endothelium and vascular spasm. Vasa 1984;13:1260-5.
48. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
49. Green D, Maliekel K, Sushko E, Akhtar R, Soff GA. Activated protein C resistance in cancer patients. Haemostasis. In press.
50. Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cis-platin. Cancer 1990;65:885-9.
51. Rella C, Coviello M, Giotta F, Maiello E, Colavito P, Colangelo D, et al. A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 1996;40:151-9.
52. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-94.
53. Rickles FR, Edwards RL, Barb C, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Cancer 1983; 51:301-7.
54. Mosesson MW, Colman RW, Sherry S. Chronic intravascular syndrome. N Engl J Med 1968;278:815-21.
55. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1995;70:725-33.
56. Callander N, Rapaport SI. Trousseau's syndrome. West J Med 1993;158:364-71.
57. Damus PS, Wallace GA. Immunologic measurement of antithrombin III, heparin cofactor and alpha-2 macroglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy. Thromb Res 1976;56:1-37.
58. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by anti-thrombin III-independent inhibitors. J Clin Invest 1990; 86:385-91.
59. Hirsh J. Heparin. N Engl J Med 1991;324:1565-74.
60. Hirsh J, Levine MN. Low-molecular-weight heparin. Blood 1992;79:1-17.
61. Calligaro KD, Bergen WS, Haut MJ, Savares RP, Laurentis DA. Thromboembolic complications in patients with advanced cancer: anticoagulation versus Greenfield filter placement. Ann Vasc Surg 1991;5:186-9.
62. Cohen JR, Tenebaum N, Citron M. Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer. Surgery 1991;109:12-5.
63. Hull RD, Rascob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992; 326:975-82.
64. Kakkar VV. Prevention and management of venous thrombosis. Br Med Bull 1994;50:871-903.
65. Barzu T, van Rijn Jr., Rosenbaum J, Tobelem G. Endothelial cell reactions with heparin. Med J Aust 1986;144(Suppl):HS15-17.
66. Dryjski M, Mikat E, Bjornsson TD. Inhibition of intimal hyperplasia after arterial injury by heparins and heparinoids. J Vasc Surg 1988;8:623-33.
67. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Tech M, et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
68. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to Coumarin. Thromb Haemost 1994;72:7-11.
69. Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or heparin fragment in the presence of cortisone. Science 1983;221:719-25.
70. Stein CA, LaRocca RV, McAfee N, Myers CE. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 1989;7:499-508.
71. Regelson W. Anionic dyes, heparin and heparinoids: the rediscovery of polyanionic tumor inhibitors. J Natl Cancer Inst 1989;81:1929-30.
72. Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-5.
73. Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist S, Lockner D, Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990;64:506-10.
74. de Valk HW, Banga JD, Wester JWJ, Brouwer CB, van Hessen MWJ, Meuwissen O, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. Ann Intern Med 1995;123:1-9.
75. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996;334:678-82.
76. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7.
77. Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight heparin versus standard heparin [letter]. Lancet 1992;339:1476.